Showing 1 to 1 of 1 results |    
Keyword Search
Results Category/Section
The Great Neuro-Pipeline Brain Drain - Why Big Pharma Hasn't Given Up On CNS Disorders

Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue. A novel Alzheimer’s disease (AD) medication bears every promise of outshining the likes of Lipitor in blockbuster status, but its chances of reaching the market are also nearly 50% lower, and development costs 30% higher, than those of its cardiovascular counterpart.